Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)

NCT04925804 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2021-12-29

No results posted yet for this study

Summary

Observational study to perform Whole Genome Sequencing in participants clinically suspected for HPP and negative for known pathogenic ALPL variants

Conditions

  • Hypophosphatasia

Sponsors & Collaborators

  • Alexion Pharmaceuticals, Inc.

    collaborator INDUSTRY
  • CENTOGENE GmbH Rostock

    lead INDUSTRY

Principal Investigators

  • Peter Bauer, Prof. Dr. · CENTOGENE GmbH

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-02
Primary Completion
2021-12-02
Completion
2021-12-02

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04925804 on ClinicalTrials.gov